The Journal of Urology
Volume 177, Issue 6 , Page 2145, June 2007

Editorial Comment

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-5347(07)00715-X

doi:10.1016/j.juro.2007.01.265

Refers to article:

  • A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer

    Michael Krainer, Sandra Tomek, Katarzyna Elandt, Peter Horak, Walter Albrecht, Michael Eisenmenger, Wolfgang Höltl, Paul Schramek, Walter Stackl, Christoph Zielinski, Jochen Reibenwein
    The Journal of Urology June 2007 (Vol. 177, Issue 6, Pages 2141-2145)

The Journal of Urology
Volume 177, Issue 6 , Page 2145, June 2007

Article Tools